Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ertong Qingfei is a Traditional Chinese Medicine (TCM) preparation developed by the First Teaching Hospital of Tianjin University of Chinese Medicine, specifically formulated for pediatric respiratory ailments. It is primarily indicated for the treatment of bronchial asthma and acute upper respiratory tract infections (URTI) in children. The formulation is designed to clear heat, ventilate the lungs, and resolve phlegm, which translates pharmacologically to anti-inflammatory, antitussive, and bronchodilatory activities. It typically contains a complex mixture of herbal extracts, often including *Ephedra sinica*, *Scutellaria baicalensis*, and *Armeniaca sibirica*. These components work synergistically to alleviate symptoms such as fever, cough with yellow sputum, and shortness of breath. As an in-hospital preparation, it is a staple in the clinical management of pediatric respiratory distress within the developing institution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ertong Qingfei.